Ascyrus Medical LLC. Recruits Top Aortic Device Industry Leader

B2B Training: What’s the Most Effective Way of Learning?

B2B training, which is short for business-to-business training, is a popular and convenient type of training that enables entire companies to train their teams...

AlixPartners Forecasts: Household Products Could Cost U.S. Manufacturers and Consumers 15% More This Year Due to Resin Shortage

While companies can’t control the market forces at play, they can take action to mitigate the risk and impact of supply chain disruption.

Ascyrus Medical LLC, the developer of novel therapies for the treatment of aortic dissection, has appointed Mr. Philip Nowell as Senior Vice President of Global Business Strategy and to the Board of Managers. The addition of Mr. Nowell to the Executive Management Team is an important reflection of the growth and expansion of the commercial infrastructure of Ascyrus Medical LLC.

“The appointment of Mr. Nowell is a very exciting and key development in preparing for the launch and commercialization of the Ascyrus Medical Dissection Stent (AMDS) and the growth of Ascyrus Medical,” said Dr. Ali Shahriari, President and CEO of Ascyrus Medical LLC. Dr. Shahriari further added, “Mr. Nowell brings decades of medical device industry knowledge and expertise, in particular in the field of treatment of aortic diseases and his addition to our team is a significant milestone for Ascyrus Medical.”

Discussing his appointment, Mr. Philip Nowell stated, “I am both excited and honored to be joining the commercial team at Ascyrus Medical. Dr. Shahriari and I make a great team, we share a passion for seeking solutions to aortic dissection and have formed a great clinical & commercial collaboration. Finding a solution to Type A dissection is an unresolved issue for me. I look forward to helping Ascyrus Medical drive forward to offer patients, their families and their doctors, solutions to Type A dissection.”

Dr. Shahriari further added: “We are extremely excited about being on the verge of changing the standard of care for patients with DeBakey I (type A) dissections for the first time in decades, and the addition of Mr. Nowell to the Ascyrus team will ensure a very effective pathway to bring this game changing therapy to all the patients suffering from acute aortic dissections.”

Philip Nowell
Mr. Nowell’s experience includes the successful launch and scale-up of two disruptive medical device technologies that established new clinical gold standards on a global basis.

Mr. Nowell was involved in the laparoscopic/thoracoscopic technology launched as Ethicon-Endosurgery at Johnson & Johnson and the world-leading aortic stent endografting technology launched as Aortic Interventions at Cook Medical.

With ten years leadership experience guiding the global scale-up of Cook Medical’s aortic stent endograft business, Mr. Nowell has developed extensive expertise in the aortic device commercialization space. Starting in 2004, Philip built the North American sales network for the aortic business at Cook Medical before moving into the global leadership role in the AI SBU responsible for all aspects of the business across 80 countries.

In addition to medical devices, Mr. Nowell’s commercial career has included sales & marketing, business development, acquisition & merger and Executive roles across pathology, private hospitals and medical centres. Philip’s health sector commercial experiences are complemented by his clinical practice experience earlier in his career before moving into industry.

Mr. Nowell’s global healthcare experience has developed clinical, health service & medical device expertise. A broad health service perspective combined with industry leadership & experience in the aortic commercial space makes Mr. Nowell’s expertise of great value to Ascyrus Medical LLC.



Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.